ADIAL PHARMACEUTICALS INC

ADIL is the ticker symbol for Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Shares trade on the Nasdaq Capital Market. The company focuses on developing treatments for addiction and related disorders. As a small-cap biotech, ADIL's stock is often driven by clinical trial updates, regulatory news, and financing activities rather than commercial product revenue.

ADIL operates in the biotechnology and pharmaceutical industry, specifically within the clinical-stage drug development segment. The company is focused on treatments for alcohol use disorder and other addictive disorders. Because it is a research-driven biotech, its business depends heavily on clinical trials, regulatory approvals, and intellectual property rather than marketed products.

The 52-week range shows the lowest and highest prices at which ADIL has traded over the past year. This figure is updated regularly and can be found in the key statistics section of the ADIL stock page. It helps investors gauge recent price volatility, though it does not predict future price movement.

ADIL stock can be highly volatile because it is a small-cap, clinical-stage biotech with no approved products generating revenue. Share prices often react sharply to clinical trial results, regulatory decisions, financing announcements, and changes in investor sentiment. Trading volume and liquidity may also be lower than larger, more established companies.

ADIL does not currently pay dividends. As a clinical-stage biopharmaceutical company, it typically reinvests any available capital into research, development, and clinical trials rather than returning cash to shareholders. For the most current dividend status, check the dividend section of the ADIL stock page.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, ADIL may also face limited liquidity, competition from larger pharmaceutical companies, and dependence on key personnel. These factors can lead to significant price swings.